A retrospective case-control study on menstrual cycle changes following COVID-19 vaccination and disease

iScience, Год журнала: 2023, Номер 26(4), С. 106401 - 106401

Опубликована: Март 15, 2023

There has been increasing public concern that COVID-19 vaccination causes menstrual disturbance regarding the relative effect of compared to SARS-CoV-2 infection. Our objectives were test potential risk factors for reporting cycle changes following and compare parameters disease. We performed a secondary analysis retrospective online survey conducted in UK March 2021. In pre-menopausal vaccinated participants (n = 4,989), 18% reported after their first vaccine injection. The prevalence any was higher women who smoke, have history disease, or are not using estradiol-containing contraceptives. second sample including both unvaccinated 12,579), alone associated with abnormal parameters, while disease an increased heavier bleeding, "missed" periods, inter-menstrual bleeding.

Язык: Английский

---

Menstrual abnormalities after COVID-19 vaccines: A systematic review

Vacunas, Год журнала: 2022, Номер 23, С. S77 - S87

Опубликована: Июль 19, 2022

Язык: Английский

---

Covid-19 vaccination and menstrual cycle length in the Apple Women’s Health Study

npj Digital Medicine, Год журнала: 2022, Номер 5(1)

Опубликована: Ноя. 2, 2022

COVID-19 vaccination may be associated with change in menstrual cycle length following vaccination. We estimated covariate-adjusted differences mean (MCL), measured days, between pre-vaccination cycles, and post-vaccination cycles within vaccinated participants who met eligibility criteria the Apple Women's Health Study, a longitudinal mobile-application-based cohort of people U.S. manually logged cycles. A total 9652 (8486 vaccinated; 1166 unvaccinated) contributed 128,094 (median = 10 per participant; inter-quartile range: 4-22). Fifty-five percent received Pfizer-BioNTech's mRNA vaccine, 37% Moderna's 8% Johnson & Johnson/Janssen (J&J) vaccine. was small increase MCL for which first dose (0.50 95% CI: 0.22, 0.78) second (0.39 0.11, 0.67) vaccines compared Cycles single J&J administered were, on average, 1.26 days longer (95% 0.45, 2.07) than Post-vaccination returned to average length. Estimated follicular phase increased (0.97 0.53, 1.42) or (1.43 1.06, 1.80) (2.27 1.04, 3.50), Menstrual appears temporary should not discourage individuals from becoming vaccinated.

Язык: Английский

---

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study

The Lancet Digital Health, Год журнала: 2022, Номер 4(9), С. e667 - e675

Опубликована: Авг. 9, 2022

BackgroundAnecdotal reports of menstrual irregularities after receiving COVID-19 vaccines have been observed in post-authorisation and post-licensure monitoring. We aimed to identify classify vaginal bleeding vaccination submitted a voluntary active surveillance system.MethodsThis observational cohort study included recipients vaccine who were aged 18 years older reported their health experiences v-safe, smartphone-based system for monitoring safety the USA, from Dec 14, 2020, Jan 9, 2022. Responses survey questions on reactions extracted, pre-trained natural language inference model was used free-text comments related menstruation response an open-ended prompt about any symptoms at intervals vaccination. Related responses further categorised into themes timing, severity, perimenopausal postmenopausal bleeding, resumption menses, other responses. examined associations between symptom theme respondent characteristics, including type dose number received, solicited local systemic reported, care sought.Findings63 815 respondents or which 62 679 female (1·0% 5 975 363 ≥18 years). Common identified timing (70 981 [83·6%] responses) severity (56 890 [67·0%] responses). Other menopausal (3439 [4·0%] menses (2378 [2·8%] Respondents submitting more likely seek than those themes.InterpretationReports heterogeneous are being although this is unable characterise relationship these Methods that leverage pretrained models interpret unsolicited signs offer promise initial evaluation unexpected adverse events potentially associated with use newly authorised licensed vaccines.FundingCenters Disease Control Prevention.

Язык: Английский

---

Impact of coronavirus disease 2019 (COVID‐19) vaccination on menstrual bleeding quantity: An observational cohort study

BJOG An International Journal of Obstetrics & Gynaecology, Год журнала: 2023, Номер 130(7), С. 803 - 812

Опубликована: Апрель 10, 2023

Abstract Objective To assess whether coronavirus disease 2019 (COVID‐19) vaccination impacts menstrual bleeding quantity. Design Retrospective cohort. Setting Five global regions. Population Vaccinated and unvaccinated individuals with regular cycles using the digital fertility‐awareness application Natural Cycles°. Methods We used prospectively collected cycle data, multivariable longitudinal Poisson generalised estimating equation (GEE) models multinomial logistic regression to calculate adjusted difference between groups. All were for confounding factors. Main outcome measures The mean number of heavy days (fewer, no change or more) changes in quantity (less, at three time points (first dose, second dose post‐exposure menses). Results included 9555 (7401 vaccinated 2154 unvaccinated). About two‐thirds reported days, regardless status. After adjusting factors, there significant differences by A larger proportion experienced an increase total (34.5% unvaccinated, 38.4% vaccinated; 4.0%, 99.2% CI 0.7%–7.2%). This translates estimated 40 additional people per 1000 normal who experience a greater following first vaccine dose' suffice. Differences resolved post‐exposure. Conclusions small probability occurred COVID‐19 which after post‐vaccination cycle. did not differ Our findings can reassure public that any are transient.

Язык: Английский

---

Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study

BMJ, Год журнала: 2023, Номер unknown, С. e074778 - e074778

Опубликована: Май 3, 2023

To evaluate the risks of any menstrual disturbance and bleeding following SARS-CoV-2 vaccination in women who are premenopausal or postmenopausal.A nationwide, register based cohort study.All inpatient specialised outpatient care Sweden from 27 December 2020 to 28 February 2022. A subset covering primary for 40% Swedish female population was also included.2 946 448 aged 12-74 years were included. Pregnant women, living nursing homes, with history menstruation disorders, breast cancer, cancer genital organs, underwent a hysterectomy between 1 January 2015 26 excluded.SARS-CoV-2 vaccination, by vaccine product (BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 (AZD1222)) dose (unvaccinated first, second, third dose) over two time windows (one seven days, considered control period, 8-90 days).Healthcare contact (admission hospital visit) before after menopause (diagnosed International Statistical Classification Diseases Related Health Problems, Tenth Revision codes N91, N92, N93, N95).2 580 007 (87.6%) 2 received at least one 652 472 (64.0%) vaccinated three doses end follow-up. The highest postmenopausal observed dose, days risk window (hazard ratio 1.28 (95% confidence interval 1.01 1.62)) (1.25 (1.04 1.50)). impact adjustment covariates modest. Risk suggested 23-33% increased BNT162b2 mRNA-1273 but association less clear. For premenopausal, almost completely removed weak associations noted crude analyses.Weak inconsistent healthcare contacts postmenopausal, even evidence recorded an premenopausal. These findings do not provide substantial support causal related disorders.

Язык: Английский

---

Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination

Vaccine, Год журнала: 2023, Номер 41(36), С. 5271 - 5282

Опубликована: Июль 3, 2023

Many signals of menstrual disturbances as possible side effects vaccination against COVID-19 have been reported. Our objective was to compare the risk before and after among women aged 18-30 years in Oslo, Norway. We used electronic questionnaires collect reports from 3972 years, participating population-based Norwegian Young Adult Cohort. examined occurrence (heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, longer spot bleedings, stronger pain during menstruation, period without bleeding) first second dose vaccine. Relative risks (RR) according were estimated using a self-controlled case-series design. performed additional analyses stratified by vaccine brand, contraception/hormone use, presence gynecological condition(s). The prevalence any disturbance 36.7% last cycle prior dose. RR for heavier usual 1.90 (95% CI: 1.69-2.13) 1.84 (1.66-2.03) Increased menstruation also observed both doses. RRs did not differ with or condition(s) disturbances. Menstrual common regardless vaccination. found increased vaccination, particularly pain. In future, characteristics should be included trials.

Язык: Английский

---

COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study

Vaccine, Год журнала: 2023, Номер 41(29), С. 4327 - 4334

Опубликована: Июнь 1, 2023

Язык: Английский

---

Association between COVID-19 vaccination and menstruation: a state of the science review

BMJ Sexual & Reproductive Health, Год журнала: 2024, Номер 50(3), С. 212 - 225

Опубликована: Июнь 10, 2024

Menstrual health is a key patient-reported outcome beyond its importance as general indicator of and fertility. However, menstrual function was not measured in the clinical trials COVID-19 vaccines. The purpose this review to synthesise existing literature on relationship between vaccination outcomes.

Язык: Английский

---

Messenger RNA Therapy for Female Reproductive Health

Molecular Pharmaceutics, Год журнала: 2024, Номер 21(2), С. 393 - 409

Опубликована: Янв. 8, 2024

Female reproductive health has traditionally been an underrepresented area of research in the drug delivery sciences. This disparity is also seen emerging field mRNA therapeutics, a class medicines that promises to treat and prevent disease by upregulating protein expression body. Here, we review advances therapies through lens improving female health. Specifically, begin our discussing fundamental structure biochemical modifications associated with mRNA-based drugs. Then, discuss various packaging technologies, including lipid nanoparticles, can be utilized protect transport drugs target cells Last, conclude usage therapy for addressing pregnancy-related vaccination against sexually transmitted diseases women. Of note, highlight relevant clinical trials using while providing their corresponding National Clinical Trial identifiers. In undertaking this review, aim provide background understanding its specifically address issues overarching goal information toward gender certain aspects research.

Язык: Английский

---